Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates Nitrated ...

In downstream processing of biopharmaceutical products, protein aggregation presents one of the main risks in terms of ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.56, a high estimate of ...

Researchers found a protein that's essential for an enterovirus to enter human cells. Although not the infamous example—that ...

A study from Cornell researchers could enable a quantum leap forward in identifying and deciphering cancer-driving genetic ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Analysts have recently evaluated Keros Therapeutics and provided 12-month price targets. The average target is $28.57, ...

Learn more about whether Corcept Therapeutics Incorporated or Sanofi is a better investment based on AAII's A+ Investor ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

A University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein RAD52 as it binds and ...

Larimar stock is down over 50% this year due to anaphylactic reactions in a study, rising expenses, and cautious market ...

Learn more about whether CRISPR Therapeutics AG or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.